Related Experiment Video

Updated: Jun 17, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Polymorphisms in PARP, IL1B, IL4, IL10, C1INH, DEFB1, and DEFA4 in meningococcal disease in three populations

Marieke Emonts1, Clementien L Vermont, Jeanine J Houwing-Duistermaat

  • 1Department of Pediatrics, Erasmus MC-Sophia Children's Hospital, University Medical Center, Dr Molewaterplein 60, Rotterdam, The Netherlands. m.emonts@erasmusmc.nl

Shock (Augusta, Ga.)
|December 18, 2009
PubMed

Insights

Genetic variations in immune response genes like DEFB1, IL4, and C1INH may influence susceptibility to meningococcal disease. Some genotypes were linked to increased risk and hematological failure in pediatric patients.

Area of Science:

  • Immunogenetics
  • Pediatric Infectious Diseases
  • Molecular Biology

Background:

  • Meningococcal infections involve complex immune pathways, including complement activation and inflammatory mediators.
  • Genetic factors may play a role in determining individual susceptibility and disease severity.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in immune-related genes and the risk/severity of pediatric meningococcal infections.
  • To analyze variations in genes encoding complement system components, inflammatory mediators, and antimicrobial peptides.

Main Methods:

  • Case-control and family-based transmission disequilibrium test (TDT) studies were conducted in Caucasian cohorts from the UK and Netherlands.
  • Polymorphisms in poly (ADP-ribose) polymerase (PARP), C1 inhibitor (C1INH), IL4, IL10, IL1B, alpha-defensin 4, and beta-defensin 1 (DEFB1) were analyzed.

Main Results:

  • The DEFB1 -44 G/G genotype was overrepresented in UK meningococcal disease cases (OR, 1.57).
  • TDT analysis suggested an association and linkage of IL4 -524 and C1INH 480 polymorphisms with susceptibility.
  • Hematological failure was more frequent in UK patients with the DEFB1 -44 G/G genotype (OR, 2.17).

Conclusions:

  • Conflicting results for DEFB1, IL4, and C1INH warrant further investigation into their precise roles in meningococcal disease susceptibility and severity.
  • Genetic polymorphisms in immune response genes represent potential factors influencing pediatric meningococcal infection outcomes.

More Related Videos

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...